Course Summary
Contact Hour(s):
1.5 Contact Hours, including 1.5 Advanced Pharmacology Hours
Author:
Julie Derringer, PhD-c, RN, CEN
This peer-reviewed course is applicable for the following professions:
Advanced Practice Registered Nurse (APRN), Certified Nurse Midwife, Certified Nurse Practitioner, Certified Registered Nurse Anesthetist (CRNA), Certified Registered Nurse Practitioner, Clinical Nurse Specialist (CNS), Licensed Practical Nurse (LPN), Licensed Vocational Nurses (LVN), Midwife (MW), Nursing Student, Registered Nurse (RN), Registered Nurse Practitioner
Accreditations:
The American Nurses Credentialing Center (ANCC)
State Approvals:
Alabama, Provider #ABNP1485; California BRN Provider #CEP # 13509; Kentucky Board of Nursing Provider #7-0085; Florida Board of Nursing Provider 50-353
Course Description:
This course discusses the recognition and management of drug overdose, including new and emerging agents. Topics include traditional drugs of abuse as well as synthetic opioids, nitazenes, novel benzodiazepines, designer stimulants, and xylazine. Course content focuses on differentiating and defining major toxidromes, identifying appropriate antidotes, recognizing when to institute supportive care, and recognizing the limitations of toxicology screening. This course includes an overview of recent legislative and public health changes that have occurred, and uses a real-world case to emphasize critical clinical decision-making skills to improve patient care.
Outcomes:
≥ 92% of participants will know how to recognize key toxidromes and antidotes.
Objectives
After completing this continuing education course, the participant will be able to:
- Improve their ability to identify traditional and emerging toxidromes.
- Ensure the use of correct naloxone dosing protocols.
- Integrate updated laws and policies into patient care plans and documentation.
- Summarize targeted testing and clinical diagnosis supported by toxidrome recognition.
- Identify evidence-based supportive care and symptom management.
Disclosures:
CEUFast Inc. and the course planning team for this educational activity do not have any relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.